Compounds > etravirine
Page last updated: 2024-09-05

etravirine and ritonavir

etravirine has been researched along with ritonavir in 58 studies

Compound Research Comparison

Studies
(etravirine)		Trials
(etravirine)		Recent Studies (post-2010)
(etravirine)		Studies
(ritonavir)		Trials
(ritonavir)		Recent Studies (post-2010) (ritonavir)
572903215,4191,2912,772

Protein Interaction Comparison

ProteinTaxonomyetravirine (IC50)ritonavir (IC50)
Solute carrier organic anion transporter family member 2B1 Homo sapiens (human)6.1
Bile salt export pumpHomo sapiens (human)2.085
ATP-dependent translocase ABCB1Homo sapiens (human)2.65
Cytochrome P450 3A4Homo sapiens (human)0.1623
Cytochrome P450 2D6Homo sapiens (human)2.3
Cytochrome P450 2C9 Homo sapiens (human)2.458
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)0.067
Substance-K receptorHomo sapiens (human)2.622
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)2.35
Thromboxane-A synthase Homo sapiens (human)0.076
Multidrug and toxin extrusion protein 2Homo sapiens (human)4.4
Multidrug and toxin extrusion protein 1Homo sapiens (human)2.1933
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)4.4
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)2
Protease Human immunodeficiency virus 14.9253

Research

Studies (58)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (15.52)29.6817
2010's44 (75.86)24.3611
2020's5 (8.62)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Converso, A; Daublain, P; El Marrouni, A; Kesisoglou, F; Lipert, MP; Templeton, AC; Wuelfing, WP1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Boffito, M; Fletcher, C; Gazzard, B; Hoetelmans, R; Jackson, A; Miralles, D; Moyle, G; Nelson, M; Pozniak, A; Tolowinska, I; Winston, A1
De Smedt, G; Hoetelmans, RM; Kakuda, TN; Lefebvre, E; Peeters, M; Schöller-Gyüre, M; Sekar, V; Woodfall, B1
Cerini, C; Fasan, S; Giacomet, V; Marchetti, G; Meroni, L; Pradella, A; Vanzulli, A; Viganò, A; Zuccotti, GV1
Kakuda, TN; Kearney, BP; Mack, R; Ramanathan, S; West, S1
Arazo Garcés, P; Omiste Sanvicente, T1
Bernardini, C; Bruzzone, B; Di Biagio, A; Icardi, G; Rosso, R; Secondo, G; Viscoli, C1
Jennings, SH; Kashuba, AD; Rezk, NL; White, NR1
Bollens, D; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Pialoux, G; Piketty, C; Roquebert, B; Taburet, AM; Yazdanpanah, Y1
Arribas, JR1
Castagna, A; De Wit, S; Florence, E; Hill, A; Marks, S; Ribera, E; van Delft, Y; Vanaken, H1
Appelbaum, JS; Bellman, P; Gathe, J; Gottlieb, MS; Hoogstoel, A; Lalezari, J; Nijs, S; Ryan, R; Sension, MG; Towner, W; Van Solingen-Ristea, R; Witek, J; Wohlfeiler, M1
Hull, MW; Montaner, JS1
Beijnen, JH; Huitema, AD; Mulder, JW; Ter Heine, R; van Gorp, EC; Wagenaar, JF2
DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J1
Brun-Vézinet, F; Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Roquebert, B; Taburet, AM; Yazdanpanah, Y1
Azijn, H; Daems, B; de Béthune, MP; Nijs, S; Picchio, G; Tambuyzer, L; Vingerhoets, J1
Corbett, C; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Nijs, S; Peeters, MP; Schöller-Gyüre, M; Snoeck, E; Vingerhoets, J; Vis, P; Wade, JR; Woodfall, BJ1
Barrail-Tran, A; Bollens, D; Chêne, G; Colin, C; Descamps, D; Fagard, C; Goldwirt, L; Katlama, C; Molina, JM; Piketty, C; Taburet, AM; Yazdanpanah, Y1
Clotet, B; Grinsztejn, B; Haubrich, R; Katlama, C; Mills, A; Molina, JM; Nijs, S; Towner, W; Trottier, B; Vingerhoets, J; Witek, J; Woodfall, B1
Alas, B; Perniciaro, A; Ruane, P; Ryan, R; Witek, J1
Bravo, I; Clotet, B; Domingo, P; Ferrer, E; Imaz, A; Llibre, JM; Podzamczer, D; Ribera, E; Santos, JR; Videla, S1
Falcon, R; Jennings, S; Kashuba, A; Mrus, J; Patterson, K1
Annaert, P; Augustijns, P; Bevernage, J; Brouwers, J; Forier, T; Tack, J1
Giguère, P; Kravcik, S; la Porte, CJ; Toy, J1
Abel, S; Davis, J; Hamlin, J; Hoetelmans, RM; Kakuda, TN; Mack, R; Ndongo, N; Petit, W; Ridgway, C; Schöller-Gyüre, M; Sekar, V; Tweedy, S1
Cattaneo, D; Gervasoni, C1
Borland, J; Chen, S; Lou, Y; Min, S; Patel, P; Piscitelli, SC; Song, I; Wajima, T1
Brogan, AJ; Martin, S; Mauskopf, J; Talbird, SE1
Dronda, F; García-Blázquez, V; Lourido-García, D; Vicente-Bártulos, A1
Boven, K; Esposito, S; Feiterna-Sperling, C; Giaquinto, C; Kakuda, TN; Königs, C; Leemans, R; Mack, R; Peeters, I; Peeters, M; Rosso, R; Sinha, R; Viscoli, C1
Hodder, S; Jayaweera, D; Mrus, J; Ryan, R; Witek, J1
Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Rami, A; Vittecoq, D; Yazdanpanah, Y; Yeni, P1
Asher Prince, HM; Brown, KC; Cohen, MS; Jennings, SH; Kashuba, AD; Malone, SA; Patterson, KB; Shaheen, NJ; Spacek, M1
Bigoloni, A; Carini, E; Castagna, A; Cossarini, F; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Piatti, P; Salpietro, S; Spagnuolo, V; Vinci, C1
Dhiver, C; Durant, J; Gagnieu, MC; Garraffo, R; Katlama, C; Lê, MP; Muret, P; Peytavin, G; Poizot-Martin, I; Solas, C; Yeni, P1
Allavena, C; Bouquié, R; Dailly, E; Deslandes, G; Jolliet, P; Raffi, F1
Akuma, SH; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Schöller-Gyüre, M; Spittaels, K; Vyncke, V; Witek, J1
DeMasi, R; Kakuda, TN; Mohammed, P; van Delft, Y1
Aga, E; Bartlett, J; Katzenstein, D; Kumarasamy, N; Norton, M; Ribaudo, H; Saravanan, S; Stevens, W; Wallis, CL1
Anderson, D; Brinson, C; Cho, M; Coate, B; Kakuda, TN; Ramgopal, M; Ruane, PJ; Ryan, R1
Bateson, R; Calvez, V; Ceccherini-Silberstein, F; Clotet, B; Cozzi-Lepri, A; Flandre, P; Grarup, J; Günthard, HF; Hoogstoel, A; Incardona, F; Kaiser, R; Lavreys, L; Ledergerber, B; Lundgren, J; Marcelin, AG; Mercedes Santoro, M; Nelson, M; Nijs, S; Opsomer, M; Paredes, R; Perno, CF; Sonnerborg, A; Tambuyzer, L; Vingerhoets, J1
Andrade, A; Eron, JJ; Fichtenbaum, CJ; Gandhi, RT; Haubrich, RH; Johnson, VA; Klingman, KL; Mollan, KR; Na, L; Smeaton, L; Tashima, KT1
Flores-Ruiz, E; Huerta-García, G; Mata-Marín, JA; Peregrino-Bejarano, L; Solórzano-Santos, F; Vazquez-Rosales, JG1
Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Fletcher, CV; Gonzalez, A; Graham, B; Hazra, R; Jean-Philippe, P; Wiznia, A; Yogev, R1
Burger, DM; D'Avolio, A; Di Perri, G; Drenth, JP; Grintjes, K; Kanter, CT; Smolders, EJ; van Crevel, R1
Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Gonzalez, A; Graham, B; Hazra, R; Jean-Philippe, P; Larson, KB; Wiznia, A; Yogev, R1
Arca, HÇ; Dahal, D; Edgar, KJ; Mosquera-Giraldo, LI; Taylor, LS1
Bruno, S; Corrigan, B; Letsie, M; Mthethwa, N; Mukui, I; Mulenga, L; Rakhmanina, N1
Chéret, A; Costagliola, D; Girard, PM; Goujard, C; Lacombe, JM; Lahoulou, R; Potard, V; Valantin, MA1
Avihingsanon, A; Bukuru, A; Cardoso, SW; Collier, AC; Faesen, S; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hughes, MD; Kanyama, C; Kumarasamy, N; Makanga, M; Mave, V; Mellors, JW; Mngqibisa, R; Mohapi, L; Montalban, E; Mugyenyi, P; Nerette Fontain, S; Ritz, J; Salata, R; Samaneka, W; Santos, BR; Schooley, RT; Secours, R; Sugandhavesa, P; Valencia, J; van Schalkwyk, M; Wallis, CL; Wangari Ndege, B; Wieclaw, L1
Appeltans, B; Pas, T; Van den Mooter, G; Verbert, S1
Alvero, CG; Barroso Hofer, C; Costello, DG; Crauwels, HM; Fairlie, L; George, KH; Graham, B; Kiser, JJ; Lypen, K; MacBrayne, CE; Moye, J; Opsomer, M; Reding, CA; Rutstein, RM; Tambuyzer, L; Townley, E; Vanveggel, S; Wiznia, AA; Woot de Trixhe, X1
Bellecave, P; Bonnet, F; Cazanave, C; Duffau, P; Hessamfar, M; Lazaro, E; Le Marec, F; Leleux, O; Neau, D; Nyamankolly, E; Perrier, A; Tumiotto, C; Vareil, MO; Wittkop, L1

Reviews

3 review(s) available for etravirine and ritonavir

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 10

    Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viremia

2008
Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Current opinion in HIV and AIDS, 2009, Volume: 4, Issue:6

    Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Ritonavir; Sulfonamides

2009

Trials

24 trial(s) available for etravirine and ritonavir

ArticleYear
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
    Antiviral therapy, 2007, Volume: 12, Issue:5

    Topics: Adult; Cross-Over Studies; Darunavir; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reference Values; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides

2007
Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.
    Antiviral therapy, 2008, Volume: 13, Issue:8

    Topics: Adolescent; Adult; Cross-Over Studies; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir

2008
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Nov-01, Volume: 49, Issue:9

    Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome

2009
HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
    International journal of STD & AIDS, 2010, Volume: 21, Issue:3

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Immunosuppression Therapy; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome

2010
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 53, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; United States; Viral Load

2010
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
    Antiviral therapy, 2010, Volume: 15, Issue:5

    Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome

2010
Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
    AIDS (London, England), 2010, Nov-13, Volume: 24, Issue:17

    Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load

2010
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
    Clinical pharmacology and therapeutics, 2010, Volume: 88, Issue:5

    Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Young Adult

2010
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
    Antiviral therapy, 2010, Volume: 15, Issue:7

    Topics: Adult; Anti-HIV Agents; Darunavir; Double-Blind Method; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load

2010
A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:11

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV Protease; HIV Reverse Transcriptase; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pilot Projects; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load

2010
Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:3

    Topics: Adult; Darunavir; Female; HIV Infections; Humans; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides

2011
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:5

    Topics: Adolescent; Adult; Cyclohexanes; Darunavir; Drug Interactions; Female; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Young Adult

2011
Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:7

    Topics: Adult; Drug Interactions; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Young Adult

2011
Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
    AIDS (London, England), 2012, Jan-28, Volume: 26, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Canada; CD4 Lymphocyte Count; Cost-Benefit Analysis; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV-1; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Nitriles; Pyridazines; Pyrimidines; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; Viral Load; Young Adult

2012
Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.
    AIDS (London, England), 2012, Feb-20, Volume: 26, Issue:4

    Topics: Adolescent; Anti-HIV Agents; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Seropositivity; Humans; Lopinavir; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load

2012
Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Protease Inhibitors; HIV-1; Humans; Male; Nitriles; North America; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sex Distribution; Sex Factors; Sulfonamides; Treatment Outcome; Viral Load

2012
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Drug Synergism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides

2013
Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
    Journal of clinical pharmacology, 2013, Volume: 53, Issue:2

    Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Gels; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Young Adult

2013
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
    HIV medicine, 2013, Volume: 14, Issue:7

    Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; Cross-Over Studies; Darunavir; Drug Interactions; Ethanolamines; Fluorenes; Healthy Volunteers; HIV; HIV Infections; Humans; Lumefantrine; Malaria; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides

2013
The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
    HIV medicine, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Anti-HIV Agents; Body Fat Distribution; Bone Density; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load

2015
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
    HIV medicine, 2015, Volume: 16, Issue:5

    Topics: CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Male; Meta-Analysis as Topic; Middle Aged; Nitriles; Odds Ratio; Pyridazines; Pyrimidines; Ritonavir; Spain; Sulfonamides; Switzerland; United Kingdom; Viral Load

2015
Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.
    HIV clinical trials, 2015, Volume: 16, Issue:4

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy

2015
Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
    Journal of the Pediatric Infectious Diseases Society, 2017, Sep-01, Volume: 6, Issue:3

    Topics: Adolescent; Darunavir; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Young Adult

2017
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
    The lancet. HIV, 2019, Volume: 6, Issue:9

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load

2019

Other Studies

31 other study(ies) available for etravirine and ritonavir

ArticleYear
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery.
    Journal of medicinal chemistry, 2022, 02-10, Volume: 65, Issue:3

    Topics: Administration, Oral; Animals; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Discovery; Humans; Oral Mucosal Absorption; Pharmaceutical Preparations; Solubility

2022
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
    AIDS (London, England), 2007, Jul-11, Volume: 21, Issue:11

    Topics: Adult; Anti-Retroviral Agents; Area Under Curve; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Viral Load

2007
Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1.
    Antiviral therapy, 2008, Volume: 13, Issue:6

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load

2008
Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.
    European journal of medical research, 2009, Mar-17, Volume: 14, Issue:3

    Topics: Adolescent; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome

2009
A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma.
    Talanta, 2009, Oct-15, Volume: 79, Issue:5

    Topics: Chromatography, High Pressure Liquid; Darunavir; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry

2009
Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in t
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:8

    Topics: Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Viral Load

2010
Recent FDA approvals and changes.
    AIDS patient care and STDs, 2010, Volume: 24, Issue:4

    Topics: Drug Approval; Drug Labeling; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Tablets; United States; United States Food and Drug Administration

2010
Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
    British journal of clinical pharmacology, 2010, Volume: 69, Issue:5

    Topics: Anti-HIV Agents; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Intestinal Absorption; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Salvage Therapy; Sulfonamides

2010
Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:11

    Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic; Darunavir; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation, Missense; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Ritonavir; Sequence Analysis, DNA; Sulfonamides; Treatment Failure; Viral Load

2010
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
    AIDS (London, England), 2010, Oct-23, Volume: 24, Issue:16

    Topics: Adolescent; Adult; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Young Adult

2010
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:7

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Exanthema; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load

2011
Excipient-mediated supersaturation stabilization in human intestinal fluids.
    Molecular pharmaceutics, 2011, Apr-04, Volume: 8, Issue:2

    Topics: Acetamides; Acetophenones; Adult; Body Fluids; Danazol; Excipients; Female; Fenofibrate; Humans; Intestines; Male; Nitriles; Pharmaceutical Preparations; Polymers; Pyridazines; Pyrimidines; Ritonavir; Solubility; Young Adult

2011
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.
    AIDS (London, England), 2011, Feb-20, Volume: 25, Issue:4

    Topics: Anti-Retroviral Agents; Aspergillosis; Aspergillus; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Nitriles; Pneumonia, Aspiration; Pyridazines; Pyrimidines; Ritonavir; Triazoles; Voriconazole

2011
Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.
    AIDS (London, England), 2011, Apr-24, Volume: 25, Issue:7

    Topics: Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides

2011
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.
    Bioanalysis, 2011, Volume: 3, Issue:10

    Topics: Blood Specimen Collection; Chromatography, High Pressure Liquid; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides

2011
[Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].
    Enfermedades infecciosas y microbiologia clinica, 2012, Volume: 30, Issue:4

    Topics: Adult; Anti-HIV Agents; Brain Edema; Darunavir; Diagnosis, Differential; Dideoxynucleosides; Emergencies; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Hypertension, Malignant; Hypertensive Encephalopathy; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Nitriles; Posterior Leukoencephalopathy Syndrome; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tomography, X-Ray Computed; Toxoplasmosis, Cerebral

2012
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
    Journal of acquired immune deficiency syndromes (1999), 2012, Apr-15, Volume: 59, Issue:5

    Topics: Adult; Darunavir; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides

2012
Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.
    Journal of acquired immune deficiency syndromes (1999), 2012, Oct-01, Volume: 61, Issue:2

    Topics: Adult; Anti-HIV Agents; Darunavir; Human Experimentation; Humans; Male; Nitriles; Plasma; Pyridazines; Pyrimidines; Rectum; Ritonavir; Semen; Sulfonamides; Young Adult

2012
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.
    AIDS (London, England), 2012, Sep-10, Volume: 26, Issue:14

    Topics: Anti-HIV Agents; Blood Glucose; Cyclohexanes; Darunavir; Fasting; Glucose Tolerance Test; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Insulin; Insulin Resistance; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome; Triazoles; Viral Load

2012
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:11

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Interactions; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Nitriles; Plasma; Pyridazines; Pyrimidines; Ritonavir; Triazoles

2012
Drug susceptibility and resistance mutations after first-line failure in resource limited settings.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Sep-01, Volume: 59, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Health Resources; HIV Infections; HIV-1; Humans; India; Lopinavir; Malawi; Male; Middle Aged; Mutation Rate; Nitriles; Pilot Projects; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; South Africa; Tanzania; Thailand; Treatment Failure; Young Adult

2014
Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection.
    Pediatric research, 2016, Volume: 80, Issue:1

    Topics: Adolescent; Anti-Retroviral Agents; CD4 Lymphocyte Count; Child; Darunavir; Drug Resistance, Multiple, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Nitriles; Poverty; Pyridazines; Pyrimidines; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load

2016
Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir.
    AIDS (London, England), 2016, 06-01, Volume: 30, Issue:9

    Topics: Anti-HIV Agents; Antiviral Agents; Area Under Curve; Carbamates; Coinfection; Darunavir; Diuretics; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidines; Renal Insufficiency; Ritonavir; Treatment Outcome; Valine

2016
Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
    Journal of the Pediatric Infectious Diseases Society, 2016, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Female; HIV Infections; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Young Adult

2016
Multidrug, Anti-HIV Amorphous Solid Dispersions: Nature and Mechanisms of Impacts of Drugs on Each Other's Solution Concentrations.
    Molecular pharmaceutics, 2017, 11-06, Volume: 14, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cellulose; Crystallization; Cyclopropanes; Drug Stability; Humans; Hydrophobic and Hydrophilic Interactions; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Solubility

2017
Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment.
    The Pediatric infectious disease journal, 2018, Volume: 37, Issue:7

    Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Darunavir; Eswatini; Female; HIV Infections; HIV-1; Humans; Kenya; Lesotho; Lopinavir; Male; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load; Young Adult; Zambia

2018
Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens.
    BMC infectious diseases, 2018, 07-11, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Hospitalization; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Risk; Ritonavir; RNA, Viral; Viral Load; Young Adult

2018
The influence of crushing amorphous solid dispersion dosage forms on the in-vitro dissolution kinetics.
    International journal of pharmaceutics, 2020, Jan-05, Volume: 573

    Topics: Administration, Oral; Antifungal Agents; Antiviral Agents; Biological Availability; Chemistry, Pharmaceutical; Crystallization; Drug Compounding; Drug Liberation; Equivalence Trials as Topic; Itraconazole; Nitriles; Particle Size; Pyridazines; Pyrimidines; Research Design; Ritonavir; Solubility; Therapeutic Equivalency; Triazoles; X-Ray Diffraction

2020
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age.
    AIDS (London, England), 2021, 07-15, Volume: 35, Issue:9

    Topics: Adult; Anti-HIV Agents; Child; Child, Preschool; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Treatment Outcome

2021
Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
    International journal of antimicrobial agents, 2023, Volume: 61, Issue:1

    Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Follow-Up Studies; HIV Infections; HIV-1; Humans; Raltegravir Potassium; Ritonavir; Treatment Outcome; Viral Load

2023